Welcome

NuVue Therapeutics, Inc. (NVT) is a privately held, biotechnology-driven, medical device company that has developed, and brings to market, a totally new and innovative image-guided, site-specific, drug and cryothermally mediated, regimen of cancer therapy for soft tissue tumors.

Through the integration of its three proprietary platform technologies, this unique NuVue regimen of cancer therapy was created, and has already proven through preclinical studies that, with the implementation of its methods and processes, there is enhanced performance with any drug it encapsulates. The results have repeatedly shown diminished patient side effects due to lesser levels of toxicity within the patient.

These lesser levels of toxicity and morbidity are created due to the delivery of focal and localized low dose/high concentration microencapsulated chemotherapeutics, in concert with the deposition of cryothermal effects that inherently show large increases in the effectiveness of the regimen of cancer therapies delivered - yet always assuring a better quality of life through the preservation of the patient's immune system.

With the delivery of this proprietary regimen, NVT has been able to show improved diagnosis and a lesser number of invasive treatments necessary, all the while creating measurably superior and enhanced outcomes.

From this platform, NuVue has developed product lines, as well as a regimen of therapy that will fulfill existing unmet clinical needs in oncology. When combined, they become a completely new and unique, path-breaking, Site-Specific Regimen of Cancer Therapy™.

NuVue’s vision is to “always believe in the ability to survive the odds” through innovative products dedicated to the continued creation of long-term survival rates.

Company Fact Sheet

Long-term cancer survivors.